ANG-3070 - Fibrokinase Inhibitors Program
ANG-3070 is an orally bioavailable small molecule fibrokinase inhibitor in advanced preclinical development for treatment of chronic kidney disease and polycystic kidney disease.
We discovered a class of novel kinase inhibitors that targets several cellular receptors involved in fibrosis that scars and damages organs including the kidney. Our most advanced candidate is ANG-3070, an orally bioavailable small molecule, which has shown efficacy in preclinical renal fibrosis models both alone and in combination with current standard-of-care therapy. ANG-3070 also has shown anti-fibrotic activity in fibrocystic kidney and liver disease as well as NASH with advanced fibrosis.